...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.
【24h】

Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.

机译:SERPINB13在头颈部鳞状细胞癌中的表达下调与不良的临床预后相关。

获取原文
获取原文并翻译 | 示例

摘要

Tumorigenesis of head and neck squamous cell carcinomas (HNSCC) is associated with various genetic changes such as loss of heterozygosity (LOH) on human chromosome 18q21. This chromosomal region maps a gene cluster coding for a family of intracellular serine protease inhibitors (serpins), including SERPINB13. As SERPINB13 expression in HNSCC has recently been shown to be downregulated both at the mRNA and protein levels, here we investigated if such a low SERPINB13 expression is associated with histopathological and clinical parameters of HNSCC tumors and patient survival. By generating specific antibodies followed by immunohistochemistry on a well-defined cohort of 99 HNSCC of the oral cavity and oropharynx, SERPINB13 expression was found to be partially or totally downregulated in 75% of the HNSCC as compared with endogenous expression in non-neoplastic epithelial cells. Downregulation of SERPINB13 protein expression in HNSCC was significantly associated with the presence of LOH at the SERPINB13 gene in the tumors (p = 0.006), a poor differentiation grade of the tumors (p = 0.001), the presence of a lymph node metastasis (p = 0.012), and a decreased disease-free (p = 0.033) as well as overall (p = 0.018) survival of the patients. This is the first report demonstrating that downregulation of SERPINB13 protein expression in HNSCC is positively associated with poor clinical outcome. Therefore, SERPINB13 seems to act as an important protease inhibitor involved in the progression of HNSCC.
机译:头颈部鳞状细胞癌(HNSCC)的肿瘤发生与各种遗传变化有关,例如人类18q21染色体上的杂合性(LOH)丧失。该染色体区域绘制了编码包括SERPINB13在内的细胞内丝氨酸蛋白酶抑制剂(serpins)家族的基因簇。由于最近已证明HNSCC中SERPINB13的表达在mRNA和蛋白质水平上均被下调,因此我们在这里研究了SERPINB13的这种低表达是否与HNSCC肿瘤的组织病理学和临床参数以及患者生存率相关。通过在明确定义的99个口腔和口咽HNSCC队列中产生特异性抗体,然后进行免疫组化,发现与非肿瘤上皮细胞中的内源性表达相比,SERPINB13表达在HNSCC的75%中部分或全部下调。 。 HNSCC中SERPINB13蛋白表达的下调与肿瘤中SERPINB13基因的LOH的存在显着相关(p = 0.006),肿瘤的分化程度较差(p = 0.001),淋巴结转移的存在(p = 0.012),并且患者的无病生存率(p = 0.033)和总体生存率(p = 0.018)降低。这是第一份证明HNSCC中SERPINB13蛋白表达下调与不良临床预后正相关的报告。因此,SERPINB13似乎是参与HNSCC进程的重要蛋白酶抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号